{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:45:15Z","timestamp":1786715115606,"version":"build-2736575974"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/0253-7613.190719","type":"journal-article","created":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T08:18:14Z","timestamp":1474273094000},"page":"490","source":"Crossref","is-referenced-by-count":11,"title":["Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials"],"prefix":"10.4103","volume":"48","author":[{"given":"Katarzyna","family":"Rygiel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.190719-1","first-page":"87","volume-title":"Global cancer statistics, 2012","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"key-10.4103\/0253-7613.190719-2","first-page":"vii155","volume-title":"Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines","author":"Curigliano","year":"2012","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0253-7613.190719-3","first-page":"1","volume-title":"Cardiovascular side effects of cancer therapies : a0 position statement from the Heart Failure Association of the European Society of Cardiology","author":"Eschenhagen","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"key-10.4103\/0253-7613.190719-4","first-page":"733","volume-title":"Cardio-oncology\/onco-cardiology","author":"Hong","year":"2010","journal-title":"Clin Cardiol"},{"key":"key-10.4103\/0253-7613.190719-5","first-page":"2900","volume-title":"Type II chemotherapy-related cardiac dysfunction : t0 ime to recognize a new entity","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0253-7613.190719-6","first-page":"596","volume-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"key-10.4103\/0253-7613.190719-7","first-page":"627","volume-title":"Cardioprotective role of \u00df-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients : a0 systematic review and meta-analysis","author":"Yun","year":"2015","journal-title":"Postgrad Med J"},{"key":"key-10.4103\/0253-7613.190719-8","first-page":"318","volume-title":"Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101 - Breast) : a0 randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI","author":"Pituskin","year":"2011","journal-title":"BMC Cancer"},{"key":"key-10.4103\/0253-7613.190719-9","first-page":"1671","volume-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA) : a0 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"key-10.4103\/0253-7613.190719-10","first-page":"1639","volume-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"key":"key-10.4103\/0253-7613.190719-11","first-page":"754","volume-title":"Emerging paradigms in cardiomyopathies associated with cancer therapies","author":"Ky","year":"2013","journal-title":"Circ Res"},{"key":"key-10.4103\/0253-7613.190719-12","first-page":"334","volume-title":"Doxorubicin induces senescence and impairs function of human cardiac progenitor cells","author":"Piegari","year":"2013","journal-title":"Basic Res Cardiol"},{"key":"key-10.4103\/0253-7613.190719-13","first-page":"2900","volume-title":"Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy : a0 systematic review and meta-analysis","author":"Kalam","year":"2013","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/0253-7613.190719-14","first-page":"9287","volume-title":"Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy","author":"Zhao","year":"2010","journal-title":"Cancer Res"},{"key":"key-10.4103\/0253-7613.190719-15","first-page":"16","volume-title":"Treatment of HER2-positive breast cancer : c0 urrent status and future perspectives","author":"Arteaga","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"key-10.4103\/0253-7613.190719-16","first-page":"289","volume-title":"Functional impairment of human resident cardiac stem cells by the cardiotoxic antineoplastic agent trastuzumab","author":"Barth","year":"2012","journal-title":"Stem Cells Transl Med"},{"key":"key-10.4103\/0253-7613.190719-17","first-page":"2176","volume-title":"Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer","author":"Chavez-MacGregor","year":"2015","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0253-7613.190719-18","first-page":"e002843","volume-title":"Cancer therapy-related cardiac dysfunction and heart failure: Part 2: Prevention, treatment, guidelines, and future directions","author":"Hamo","year":"2016","journal-title":"Circ Heart Fail"},{"key":"key-10.4103\/0253-7613.190719-19","first-page":"2355","volume-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies : t0 he OVERCOME trial (preventiOn of left Ventricular dysfunction with enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/0253-7613.190719-20","first-page":"809","volume-title":", Sebag IA, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","author":"Ky","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/0253-7613.190719-21","first-page":"1874","volume-title":"Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality","author":"Pavo","year":"2015","journal-title":"Heart"},{"key":"key-10.4103\/0253-7613.190719-22","first-page":"5","volume-title":"Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy","author":"Fallah-Rad","year":"2008","journal-title":"J Cardiovasc Magn Reson"},{"key":"key-10.4103\/0253-7613.190719-23","first-page":"19","volume-title":"I-123-MIBG myocardial imaging in trastuzumab-based cardiotoxicity : t0 he first experience","author":"Stokkel","year":"2013","journal-title":"Nucl Med Commun"},{"key":"key-10.4103\/0253-7613.190719-24","first-page":"2504","volume-title":"Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","author":"Chen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/0253-7613.190719-25","first-page":"2159","volume-title":"Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)","author":"de","year":"2014","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0253-7613.190719-26","first-page":"312","volume-title":"Risk of cardiac dysfunction with trastuzumab in breast cancer patients : a0 meta-analysis","author":"Chen","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"key-10.4103\/0253-7613.190719-27","first-page":"795","volume-title":"Trastuzumab-related cardiotoxicity in early breast cancer : a0 cohort study","author":"Bonifazi","year":"2013","journal-title":"Oncologist"},{"key":"key-10.4103\/0253-7613.190719-28","first-page":"897","volume-title":"Trastuzumab-related cardiotoxicity in the elderly : a0 role for cardiovascular risk factors","author":"Serrano","year":"2012","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0253-7613.190719-29","first-page":"4222","volume-title":"Trastuzumab-related cardiotoxicity among older patients with breast cancer","author":"Chavez-MacGregor","year":"2013","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0253-7613.190719-30","first-page":"141","volume-title":"Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer","author":"Russo","year":"2014","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"key-10.4103\/0253-7613.190719-31","first-page":"439","volume-title":"Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer","author":"Russo","year":"2012","journal-title":"Intern Emerg Med"},{"key":"key-10.4103\/0253-7613.190719-32","first-page":"845","volume-title":"Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer","author":"Cochet","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"key-10.4103\/0253-7613.190719-33","first-page":"e000472","volume-title":"Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","author":"Ezaz","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"key-10.4103\/0253-7613.190719-34","first-page":"493","volume-title":"Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity","author":"Negishi","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"key":"key-10.4103\/0253-7613.190719-35","first-page":"2263","volume-title":"The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy","author":"Fallah-Rad","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/0253-7613.190719-36","first-page":"614","volume-title":"Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (cardioxane) in advanced\/metastatic breast cancer patients treated with anthracycline-based chemotherapy","author":"Marty","year":"2006","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0253-7613.190719-37","first-page":"45","volume-title":"Topoisomerase 2\u00df : a0 promising molecular target for primary prevention of anthracycline-induced cardiotoxicity","author":"Vejpongsa","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.4103\/0253-7613.190719-38","first-page":"1287","volume-title":"Evaluation and management of patients with heart disease and cancer : c0 ardio-oncology","author":"Herrmann","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"key-10.4103\/0253-7613.190719-39","first-page":"1787","volume-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association (HFA) of the ESC","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"key-10.4103\/0253-7613.190719-40","first-page":"2749","volume-title":"Cancer therapy-induced cardiac toxicity in early breast cancer : a0 ddressing the unresolved issues","author":"Khouri","year":"2012","journal-title":"Circulation"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:25:14Z","timestamp":1786713914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0253-7613.190719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"alternative-id":["190719"],"URL":"https:\/\/doi.org\/10.4103\/0253-7613.190719","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}